Results 41 to 50 of about 131 (88)

Overcoming challenges of developing a live-attenuated dengue vaccine and the path forward

International Journal of Infectious Diseases
Introduction: The WHO declared dengue a grade 3 emergency, underscoring an urgent need for safe and effective vaccines. Challenges have hindered progress with such vaccines, including selection of an appropriate backbone, proper viral attenuation with ...
Dr Walid Kandeil, Dr Mayuri Sharma
doaj   +1 more source

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children

npj Vaccines
As robust cellular responses are important for protection against dengue, this phase 2 study evaluated the kinetics and phenotype of T cell responses induced by TAK-003, a live-attenuated tetravalent dengue vaccine, in 4–16-year-old living in dengue ...
Sanja Mandaric, Heather Friberg, Xavier Saez-Llorens, Charissa Borja-Tabora, Shibadas Biswal, Ian Escudero, Alice Faccin, Raphael Gottardo, Manja Brose, Nicholas Roubinis, Darlene Fladager, Rodrigo DeAntonio, Julie Anne L. Dimero, Nathali Montenegro, Nicolas Folschweiller, Jeffrey R. Currier, Mayuri Sharma, Vianney Tricou   +17 more
doaj   +1 more source

Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data

Virology Journal
Background and objectives Dengue is one of the fastest spreading arboviral infection with no specific antiviral treatment, making vaccination a significant preventive approach.
Ravi Kant, Anushka Singh, A. Babar Ali, Shweta Nagre, Nirmal Kumar Ganguly, Rashmi Rana   +5 more
doaj   +1 more source

State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature

Infectious Disease Reports
Background: Dengue virus infection is a significant challenge for global health, with 100 million symptomatic cases, 2.3 million DALYs and 20,000 deaths annually.
Davide Marangoni, Anna Barbiero, Michele Spinicci, Alessandro Bartoloni, Andrea Rossanese, Paolo Bonanni, Lorenzo Zammarchi   +6 more
doaj   +1 more source

Hypersensitivity reactions to dengue vaccine TAK-003 (Qdenga®) following an immunization campaign targeting children and adolescents [PDF]

Revista da Sociedade Brasileira de Medicina Tropical
Background: A national dengue vaccination campaign using TAK-003 was launched in 2024, targeting adolescents. Post-licensure surveillance suggested higher-than-expected hypersensitivity reactions.
Márcia Paulliny Soares Bahia, Silon de Souza Gomes Junior, Argus Leão Araújo, Hoberdan Oliveira Pereira, José Geraldo Leite Ribeiro, Alexandre Sampaio Moura   +5 more
doaj   +2 more sources

Intention to Receive the TAK-003 Dengue Vaccine and Associated Factors Among Adults in Rural Northern Thailand

Vaccines
Background: Dengue is a common mosquito-borne disease in Thailand and poses an increased risk of severe illness among adults. The TAK-003 quadrivalent dengue vaccine is newly introduced in Thailand and has demonstrated promising efficacy.
Chanachai Polpitakchai, Sipang Pangprasertkul, Pimbucha Rusmevichientong, Ranchana Yamsiri, Jinjuta Panumasvivat, Wachiranun Sirikul, Ratana Sapbamrer, Sitong Luo, Chunqing Lin, Amornphat Kitro   +9 more
doaj   +1 more source

TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses

Vaccines
Background: Torquetenovirus (TTV) viremia is increasingly recognized as a biomarker of host immune competence. We assessed the association between baseline TTV DNA levels and immune responses to the Mpox virus (MPXV) and dengue virus (DGV) vaccines in ...
Claudia Minosse, Pietro Giorgio Spezia, Sara Belladonna, Aurora Bettini, Giulia Matusali, Francesca Colavita, Stefania Notari, Linda Petrone, Marta Tiberi, Alessandro Rosario Cavasio, Valentina Mazzotta, Luigi Rosa, Eleonora Cimini, Daniele Focosi, Delia Goletti, Emanuele Nicastri, Andrea Antinori, Fabrizio Maggi   +17 more
doaj   +1 more source

Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination

Human Vaccines & Immunotherapeutics
Dengue vaccines face significant challenges, including safety concerns, which contribute to vaccine hesitancy. Addressing this complex issue requires targeted strategies to overcome existing barriers.
Rachata Charoenwisedsil, Saranath Lawpoolsri, Pinyo Rattanaumpawan, Daniel Y. T. Goh, Gerard T. Flaherty, Thundon Ngamprasertchai   +5 more
doaj   +1 more source

Dengue Vaccine Development and Deployment into Routine Immunization

Vaccines
Dengue has emerged as a significant global health threat. Despite decades of research, only two dengue vaccines—CYD-TDV (Dengvaxia) and TAK-003 (Qdenga)—have been licensed to date, with limited implementation.
Annelies Wilder-Smith, Thomas Cherian, Joachim Hombach   +2 more
doaj   +1 more source

Effectiveness and safety of the tetravalent TAK-003 dengue vaccine: a systematic review.

Medicina
In Argentina, the dengue virus has experienced an increase in recent years. This study aims to conduct a systematic review to evaluate the effectiveness and safety of the TAK-003 tetravalent dengue vaccine in this context. A systematic review of randomized controlled trials comparing the effectiveness and safety of the vaccine with placebo in the ...
Agustín, Bengolea, Clara, Scigliano, Jose T, Ramos-Rojas, Gabriel, Rada, Hugo N, Catalano, Ariel, Izcovich   +5 more
openaire   +1 more source